Pfizer Reports Q1 2025 Financial Results

In the first quarter of fiscal year 2025, Pfizer Inc. showcased its financial resilience with a revenue of $13.7 billion, marking an 8% annual decrease. Despite this, the pharmaceutical giant's strategic focus on operational efficiency and financial discipline has set a positive tone for the year ahead.

Financial Highlights

The company reported a net income of $2.97 billion, a 5% decline year-on-year, and diluted earnings per share (EPS) also saw a 5% decrease to $0.52. "We are currently trending towards the upper end of our 2025 Adjusted diluted EPS guidance range," stated CFO David Denton, highlighting the company's optimistic outlook.

Market Response

Following the announcement, Pfizer's shares experienced a 0.65% increase in premarket trading, reflecting investor confidence in the company's financial health and future prospects.